ClinicalTrials.gg
RecruitingNCT07029594CANDYUpdated Jun 19, 2025

Thermal Spa Treatment and Improvement of Primary Ciliary Dyskinesia

An interventional study of balneotherapy in Primary Ciliary Dyskinesia, sponsored by Association Francaise pour la Recherche Thermale. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-19.

Sponsored by Association Francaise pour la Recherche Thermale · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate whether a 3-week thermal spa treatment can improve quality of life and reduce ENT (ear, nose, and throat) symptoms in adults with Primary Ciliary Dyskinesia (PCD). PCD is a rare, chronic condition that affects the airways and often leads to persistent sinus, ear, and lung infections.

The main questions the study aims to answer are:

Does spa therapy improve ENT-related symptoms and daily quality of life?

Does it help reduce the frequency of infections and the need for antibiotics?

Are there improvements in hearing and lung function?

In this study, participants will be randomly assigned to one of two groups:

Group A will begin with a 3-week spa treatment, followed by regular checkups for 6 months.

Group B will start with standard care for 6 months, then receive the spa treatment and follow-up evaluations for another 6 months.

All participants will:

Undergo ENT and lung function evaluations (questionnaires, hearing tests, nasal swabs, spirometry)

Visit one of two spa centers for a 3-week treatment period (without hospital stay)

Be followed regularly over several months for checkups and tests

Researchers will compare participants' symptoms and test results before and after the spa treatment to determine its benefits.

Potential benefits:

Participants may experience relief from nasal symptoms, fewer respiratory infections, improved hearing and breathing, and an overall better quality of life.

Potential risks:

There is a small risk of infection from a new germ or a mild, short-term flare-up of chronic symptoms (called a "thermal reaction") that can occur during spa therapy.

02

Conditions studied

  • Primary Ciliary Dyskinesia
03

In context

Ciliary Motility Disorders

80 studies on the registry are indexed under Ciliary Motility Disorders; 27 are open to participants now.

This study's planned enrollment of 35 is close to the median of 32 across 24 interventional studies indexed under Ciliary Motility Disorders.

Browse Ciliary Motility Disorders studies →

Lead sponsor

Association Francaise pour la Recherche Thermale is the lead sponsor of 20 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of Primary Ciliary Dyskinesia (PCD) based on electron microscopy analysis of ciliary ultrastructure and/or genetic testing (i.e., two unambiguous mutations in genes known to be involved in PCD, particularly in cases with normal ciliary ultrastructure [\~20% of patients], atypical ultrastructural findings, or suggestive symptoms in a family with a known causal gene).
  • Age over 18 years.
  • Stable maintenance treatment for at least 1 month prior to inclusion.
  • Performance Status (PS) ≤ 1.
  • Patient has received the study information sheet and signed the form.
  • Patient has valid health insurance coverage.

Exclusion criteria

Exclusion Criteria:

  • Participation in a thermal spa treatment within the past year.
  • Severe general health deterioration or debilitating conditions.
  • Severe or recent heart failure.
  • Labile hypertension.
  • Venous insufficiency or deep vein thrombosis within the past 3 months.
  • Recent unhealed fracture.
  • Unhealed skin lesions (wounds, pressure sores, eczema).
  • Contagious or progressive diseases.
  • Recent cancer (less than 5 years).
  • Ongoing or recent (within the past month) pulmonary or ENT exacerbation at inclusion.
  • Ongoing treatment with immunomodulatory or drugs (due to the risk of potentially severe opportunistic infections).
  • Ongoing or recent (within the past month) extra-respiratory or ENT infectious flare-up.
  • Positive pre-cure bacteriological testing for multidrug-resistant Pseudomonas aeruginosa, MRSA, Mycobacterium abscessus, or other multidrug-resistant pathogenic bacteria.
  • Fever > 38.5°C.
  • Recently worsened dyspnea (\< 1 month).
  • History of serious adverse effects or intolerance during a previous thermal spa treatment.
  • Participation in another clinical trial with an exclusion period.
  • Considered a vulnerable person, as defined by Articles L1121-5 to L1121-8 of the French Public Health Code:

Pregnant women, women in labor, and breastfeeding mothers.

Individuals deprived of liberty by judicial or administrative decision, or those hospitalized without consent under Articles L.3212-1 and L.3213-1 (excluding Article L.1121-8), and persons admitted to a healthcare or social institution for reasons other than research.

Adults under legal protection or unable to give .

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    Groupe A

    Group starting with thermal spa treatment

    Other: balneotherapy

  • Experimental
    Group B

    Group starting with prophylactic treatment

    Other: balneotherapy

Interventions

  • Otherbalneotherapy

    Specific procedures performed during the 3-week spa therapy Thermal Treatments (Number of sessions) Individual nasal irrigation (18) Sonic aerosol therapy (18) Simple aerosol therapy (18) Individual inhalation therapy (18) Administered by a licensed physiotherapist Individual respiratory rehabilitation and bronchial drainage (18) Administered by a spa physician Tubo-tympanic insufflation (9) Sinus lavage using the Proëtz displacement method 9

06

What researchers measure

Primary outcomes

  1. Quality of life

    The primary objective of this study is to evaluate whether a thermal spa treatment leads to a significant improvement in quality of life, as well as in respiratory and auditory symptoms, in patients with primary ciliary dyskinesia. The primary outcome will be the improvement, after spa therapy, of a validated French-language ENT quality of life score specifically designed to assess functional complaints and quality of life in patients with conditions affecting the nasal passages.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Institut Universitaire de la Face et du Cou
    Nice, 06103, France
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2025; primary completion for Dec 2026, 15 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2025
First posted
Jun 19, 2025
StartEst.
Sep 5, 2025
Primary completionEst.
Dec 5, 2026
CompletionEst.
May 5, 2027
Last update
Jun 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07029594
Lead sponsor
Association Francaise pour la Recherche Thermale
Collaborators
Centre Antoine Lacassagne
Responsible party
Sponsor
First posted
Jun 19, 2025
Start date
Sep 5, 2025 (estimated)
Primary completion
Dec 5, 2026 (estimated)
Completion
May 5, 2027 (estimated)
Last update
Jun 19, 2025

Study contacts

Colin DEBAIGT
Contact
colin.debaigt@nice.unicancer.fr
+33492031661

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion